Print Page     Close Window     

SEC Filings

AC IMMUNE SA filed this Form 6-K on 06/28/2017
Entire Document

© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 8 AC Immune’s technology leadership Product - focused and highly productive platforms drive growth SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Immunotherapy against conformation - specific targets ▪ Antibodies and vaccines highly selective for conformational targets ▪ Rapid antibody response ▪ Favorable safety profile – T - cell independent mechanism does not trigger T - cell correlated inflammatory response ▪ 4 products in clinical development: crenezumab , ACI - 24, ACI - 35, anti - Tau antibody Hickman et al, JBC 286, 2011 Generation of conformation specific small molecules Morphomer TM Conformation sensitive small molecules ▪ Rational chemical design for small molecules that target CNS diseases ▪ Robust library of compounds with desirable properties including brain penetration ▪ Protein propagation inhibitors ▪ Proof - of - concept in animal models ▪ 5 development candidates, 1 diagnostic PET imaging tracer in clinical development


© AC Immune 2015